Cat. No. DMC100441P



PRODUCT INFORMATION

Clone ID DMC441
Target CD5L

Synonyms AIM; API6; CT-2; hAIM; PRO229; SP-ALPHA;

Spalpha

Host Species Rabbit

Description PE-conjugated Anti-CD5L antibody(DMC441); lgG1

Chimeric mAb

Delivery Under Development

Uniprot ID 043866

IgG type Rabbit/Human Fc chimeric IgG1

Clonality Monoclonal
Reactivity Human
Applications Flow Cyt

Recommended DilutionsFlow Cyt 1:100

Purification Purified from cell culture supernatant by affinity

Email: info@dimabio.com Website: www.dimabio.com

chromatography

Formulation & Reconstitution Liquid PBS with 0.05% Proclin300, 1% BSA

Storage & Shipping Store at 2°C-8°C for 6 months



Cat. No. DMC100441P



macrophages in lymphoid and inflamed tissues and regulates mechanisms in inflammatory responses; such as infection or atherosclerosis. Able to inhibit lipid droplet size in adipocytes.
Following incorporation into mature adipocytes via CD36-mediated endocytosis; associates with cytosolic FASN; inhibiting fatty acid synthase activity and leading to lipolysis; the degradation of triacylglycerols into glycerol and free fatty acids (FA). CD5L-induced lipolysis occurs with progression of obesity: participates in obesityassociated inflammation following recruitment of inflammatory macrophages into adipose tissues; a cause of insulin resistance and obesity-related metabolic disease. Regulation of intracellular lipids mediated by CD5L has a direct effect on transcription regulation mediated by nuclear

Secreted protein that acts as a key regulator of lipid synthesis: mainly expressed by

Background

receptors ROR-gamma (RORC). Acts as a key regulator of metabolic switch in T-helper Th17 cells. Regulates the expression of pro-inflammatory genes in Th17 cells by altering the lipid content and limiting synthesis of cholesterol ligand of RORC; the master transcription factor of Th17-cell differentiation. CD5L is mainly present in non-pathogenic Th17 cells; where the content of the content is the content of the content the content of polyunsaturated fatty acyls (PUFA); affecting two metabolic proteins MSMO1 and CYP51A1; which synthesize ligands of RORC; limiting RORC activity and expression of proinflammatory genes. Participates in obesityassociated autoimmunity via its association with
IgM; interfering with the binding of IgM to
Fcalpha:mu receptor and enhancing the
development of long-lived plasma cells that
produce high-affinity IgG autoantibodies (By) produce high-affinity IgG autoantibodies (By similarity). Also acts as an inhibitor of apoptosis in macrophages: promotes macrophage survival from the apoptotic effects of oxidized lipids in case of atherosclerosis (PubMed:24295828). Involved in early response to microbial infection against various pathogens by acting as a pattern recognition receptor and by promoting autophagy (PubMed:16030018; PubMed:24223991; PubMed:24583716; PubMed:25713983).

Usage Research use only

Conjugate PE-conjugated

All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to **DIMA Disclaimer**

> Email: info@dimabio.com Website: www.dimabio.com

ensure no IP infringement.

Address: Wuhan institute of Biotechnology B7, Biolake No.666 Gaoxin Road, Wuhan, Hubei, China Telephone: +1 2409940618(USA) /+86-18062749453(China)

/+86-400-006-0995(China)

